Close Menu

This article has been updated to reflect the correct proposed list price for Rozlytrek.

NEW YORK – The UK's National Institute for Health Care Excellence (NICE) on Thursday published a final draft guidance recommending the histology-independent use of entrectinib (Roche's Rozlytrek) through the Cancer Drugs Fund (CDF).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.